Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label extension study of astegolimab for long-term safety in chronic obstructive pulmonary disease
CTR20243280Phase 3Active
- Sponsor
- Roche
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of astegolimab in chronic obstructive pulmonary disease (COPD), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Started Jan 2025; status: active.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20243280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243280.